179068-02-1

PHCCC is a Group I mGluR antagonist with an IC50 of 3 μM. PHCCC is a selective positive modulator of mGlu4 receptor. Antiparkinsonian effect[1][2].

ChEBI: 7-hydroxyimino-N-phenyl-1,7a-dihydrocyclopropa[b][1]benzopyran-1a-carboxamide is a 1-benzopyran.

PHCCC is a positive allosteric modulator (PAM) at the mGluR4 subtype th at exhibits anxiolytic and anti-Parkinsonian effects in animal models. PHCCC is a potent group I metabotropic glutamate receptor antagonist.

Group I mGluR receptors: 3 μM (IC₅₀)

Store at RT

[1] Récasens M, et al. Metabotropic glutamate receptors as drug targets. Curr Drug Targets. 2007;8(5):651-681. DOI:10.2174/138945007780618544
[2] Marino MJ et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13668-73. DOI:10.1073/pnas.1835724100